Publication

Article

Oncology & Biotech News

January 2011
Volume5
Issue 1

Inconclusive Lung Cancer Screenings Prompt Smokers to Quit

Men who undergo lung cancer screening are more likely to stop smoking if the results are inconclusive than if they are negative, according to a team of researchers from Denmark.

Men who undergo lung cancer screening are more likely to stop smoking if the results are inconclusive than if they are negative, according to a team of researchers from Denmark. The smokers with CT scans that were inconclusive made 1.9 attempts to quit compared with 1.5 for those FDA Updates with negative scans. In addition, 12% of men with inconclusive screens abstained from cigarettes for a prolonged period compared with 9% of the men with negative screens. Investigators noted that the differences were not statistically significant, but they said it suggests a need for more research to determine whether lung cancer screening could be a tool to promote smoking cessation. Findings were published in the European Respiratory Journal.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.